Abstract
Sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are antihyperglycaemic agents with weight-lowering effects. The efficacy and safety of the SGLT2 inhibitor canagliflozin as add-on therapy in Japanese patients with type 2 diabetes mellitus (T2DM) and inadequate glycaemic control with a GLP-1RA (≥12 weeks) were evaluated in this phase IV study. Patients received canagliflozin 100 mg once daily for 52 weeks. Efficacy endpoints included change in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight, systolic blood pressure (SBP) and HDL cholesterol from baseline to week 52. Safety endpoints included adverse events (AEs), hypoglycaemia and laboratory tests. Of the 71 patients treated with canagliflozin, 63 completed the study. At 52 weeks, HbA1c was significantly reduced from baseline (-0.70%; paired t test, P < .001). Significant changes were also observed in FPG (-34.7 mg/dL), body weight (-4.46%), SBP (-7.90 mm Hg), and HDL cholesterol (7.60%; all P < .001). The incidence of AEs, adverse drug reactions and hypoglycaemia was 71.8%, 32.4% and 9.9%, respectively. All hypoglycaemic events were mild. These findings suggest that the long-term combination of c...Continue Reading
References
Mar 30, 2007·Diabetes Care·Hiroki YokoyamaUNKNOWN Japan Diabetes Clinical Data Management Study Group
Nov 6, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Hiroki YokoyamaUNKNOWN Japan Diabetes Clinical Data Management Study Group
Nov 15, 2011·Diabetes, Obesity & Metabolism·A J Garber
Apr 25, 2012·Diabetologia·S E InzucchiD R Matthews
Feb 19, 2013·Diabetes Care·Sarah Stark CasagrandeCatherine C Cowie
Mar 8, 2013·Diabetes Care·UNKNOWN American Diabetes Association
Jan 1, 2014·Diabetes, Obesity & Metabolism·J Seufert, B Gallwitz
May 21, 2014·Journal of Diabetes Investigation·Akifumi KushiyamaShoji Kawazu
Jul 11, 2014·Expert Opinion on Pharmacotherapy·Nobuya InagakiHideki Kuki
Oct 25, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Kohei KakuAnna Maria Langkilde
Dec 30, 2014·Journal of the American Society of Hypertension : JASH·George Maliha, Raymond R Townsend
Mar 25, 2015·Journal of Diabetes Investigation·Nobuya InagakiHideki Kuki
Jul 17, 2015·Diabetes Care·Giulia FerranniniEle Ferrannini
Oct 10, 2015·Diabetes, Obesity & Metabolism·Greg FulcherUNKNOWN CANVAS trial collaborative group
Nov 27, 2015·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Jochen Seufert
Sep 22, 2016·The Lancet. Diabetes & Endocrinology·Juan P FríasSerge A Jabbour
Apr 23, 2017·Diabetes, Obesity & Metabolism·Ralph A DeFronzo
May 16, 2017·Journal of Diabetes Investigation·Yutaka SeinoSoichi Sakai
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Nov 8, 2017·Diabetes, Obesity & Metabolism·Nobuya InagakiHiroaki Iijima
Citations
Dec 1, 2018·Diabetes, Obesity & Metabolism·Hirotaka WatadaEiichi Araki
Dec 20, 2018·Diabetes, Obesity & Metabolism·Priyamvada SinghShumei Meng
Aug 31, 2019·Diabetes, Obesity & Metabolism·Bryony E LangfordAmarjeet Tank
Jan 5, 2020·Endocrine·Man GuoYong Xu
Nov 2, 2019·Current Drug Targets·Ping WuHao Fang
Aug 21, 2020·Diabetes Care·Serge A JabbourCristian Guja
Oct 4, 2019·Postgraduate Medicine·Rosemarie Lajara
Feb 26, 2020·Diabetes & Metabolism Journal·Wayne Huey Herng SheuKun Ho Yoon
May 26, 2018·Expert Opinion on Pharmacotherapy·Nobuya InagakiHiroaki Iijima
Aug 24, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Taichi Nagahisa, Yoshifumi Saisho
Aug 14, 2021·Expert Opinion on Pharmacotherapy·Maka Siamashvili, Stephen N Davis
May 20, 2020·Diabetes Spectrum : a Publication of the American Diabetes Association·John E Anderson